UPDATE: J.P. Morgan Lowers PT on GenMark Diagnostics on Lowered 2013 Guidance

In a report published Monday, J.P. Morgan analyst Tycho W. Peterson maintained an Overweight rating on GenMark Diagnostics GNMK and lowered the price target from $17 to $15.

In the report, J.P. Morgan cited their price target decrease to news that, “GenMark officially lowered 2013 revenue guidance from ~$35M to ~$30M, due to the uncertainties around revenues from the largest customer, Natural Molecular Testing Corporation (NMTC).”

GenMark Diagnostics closed Monday at $10.97.